HRT, breast and endometrial cancers: strategies and intervention options
- PMID: 10515669
- DOI: 10.1016/s0378-5122(98)00108-x
HRT, breast and endometrial cancers: strategies and intervention options
Abstract
The demand for hormone replacement therapy (HRT) by women who enter the menopause is rapidly increasing in all developed countries. The concern that HRT may enhance morbidity and mortality from malignant diseases still limits the widespread adoption of hormonal treatments. Overall, epidemiological data on cancer incidence and HRT are reassuring, although long-term or inappropriate therapies may slightly increase the risk of developing malignant diseases. Many commercial hormonal compounds are currently available and the safest HRT regimen with regard to cancer risk must be identified. It is equally important that the best strategies for breast and endometrial surveillance in women commencing HRT be outlined, bearing in mind that the diffusion of hormonal therapies may be halted by unnecessary medical interventions.
Similar articles
-
Use of HRT and the subsequent risk of cancer.J Epidemiol Biostat. 1999;4(3):191-210; discussion 210-5. J Epidemiol Biostat. 1999. PMID: 10695959 Review.
-
Hormone replacement therapy and cancer.Gynecol Endocrinol. 2001 Dec;15(6):453-65. Gynecol Endocrinol. 2001. PMID: 11826770 Review.
-
Exogenous steroids for menopausal symptoms and breast/endometrial cancer risk.Int J Gynecol Cancer. 2006;16 Suppl 2:494-6. doi: 10.1111/j.1525-1438.2006.00677.x. Int J Gynecol Cancer. 2006. PMID: 17010054
-
Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.Climacteric. 2001 Sep;4(3):181-93. Climacteric. 2001. PMID: 11588941 Review.
-
Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer.Lancet. 1997 Oct 11;350(9084):1047-59. Lancet. 1997. PMID: 10213546
Cited by
-
Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease.J Psychiatry Neurosci. 2002 Jan;27(1):12-27. J Psychiatry Neurosci. 2002. PMID: 11836973 Free PMC article. Review.
-
Changes in 5-HT1A receptor binding and G-protein activation in the rat brain after estrogen treatment: comparison with tamoxifen and raloxifene.J Psychiatry Neurosci. 2005 Mar;30(2):110-7. J Psychiatry Neurosci. 2005. PMID: 15798786 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical